Our partners

Target ALS does not purport to cover all bases in the struggle against ALS. Therefore, from the beginning, we have nurtured partnerships with academic institutions and pharma/biotech companies, as well as with other foundations and research organizations. We have already gained much from these partnerships and intend to pursue them actively. Only by creating synergy through early exchange of information and active strategic collaboration do we have a chance to solve this challenge in our lifetime.

Academic institutions

Universities and research institutes constitute the major reservoir of new ideas and targets for ALS. With the active and constructive involvement of their research and tech transfer administrations we are proud to have funded research in all the following institutions:

Barrow Neurological Institute, Phoenix, AZ
Baylor College of Medicine, Houston, TX
Boston Children's Hospital, Boston, MA
Brandeis University, Waltham, MA
Cedars–Sinai Medical Center, Los Angeles, CA
Columbia University, New York City, NY
Georgetown University, Washington D.C.
Gladstone Institutes, San Francisco, CA
Harvard University, Cambridge, MA
Hôpital de la Pitié Salpétrière, Paris, France
INSERM, Paris, France
Johns Hopkins University, Baltimore, MD
Ludwig Institute for Cancer Research, San Diego
Massachusetts General Hospital, Boston, MA
Mayo Clinic, Jacksonville, FL
National Institute of Environmental Health, Research Triangle Park, NC
Northwestern University, Chicago, IL
St. Jude Children’s Hospital, Memphis, TN
Stanford University, Stanford, CA
The Scripps Research Institute, Jupiter, FL
Thomas Jefferson University, Philadelphia, PA
Ulster University, Belfast, UK
University of California, San Diego, CA
University of California, San Francisco, CA
University Chicago, Chicago, IL
University Florida Gainesville, FL
University Massachusetts, Worcester, MA
University of Michigan, MI
University of North Carolina, Chapel Hill, NC
University of Oxford, Oxford, UK
University of Paris-Descartes, Paris, France
University Pennsylvania, Philadelphia, PA
University of Zurich, Zurich, Switzerland
Washington University, St. Louis, MO
University Utah, Salt Lake City, UT

Biotech and pharmaceutical companies

Increasing industry involvement was the principal initial goal of Target ALS and the degree to which this has been realized, and the intensity of their involvement, is a cause for optimism. The following companies have participated in Target ALS in one or more of the following capacities: collaborator within a research consortium, member of the Independent Review Committee, attendee at the Annual Target ALS Meeting, recipient of presentations from a group of Target ALS scientists.

AbbVie, North Chicago, IL
ADRx, Inc., Westlake Village, CA
Amgen, Thousand Oaks, CA
Amylyx Pharmaceuticals Inc., Cambridge, MA
Anida Pharma Inc., MA
AstraZeneca, London, UK
Aquinnah Pharmaceuticals, MA
Biogen, Cambridge, MA
Bristol-Myers Squibb, New York City, NY
Clarus Ventures, MA
Congenia, Milan, Italy
Denali, CA
F-Prime Capital Partners, MA
Genentech, South San Francisco, CA
Genzyme, Ridgefield, NJ
GlaxoSmithKline Clifton, NJ
Inception Sciences, CA
ISIS Pharmaceuticals Carlsbad, CA
Izumi Biosciences, Lexington, MA
Karyopharm Therapeutics, MA
Lundbeck, Valby, Denmark
MeiraGTx, NY
Merck, Kenilworth, NJ
miCure Therapeutics, Nes Ziona, Israel
Neurimmune, Switzerland
Novartis, New York City, NY
ONO Pharmaceutical Co., LTD., Osaka, Japan
Ossianix, Philadelphia, PA
Pfizer, Rye Brook, NY
Q Therapeutics, Salt Lake City, UT
Shire, Lexington, MA
Regeneron, Tarrytown, NY
Roche, Basel, Switzerland
Regulus, San Diego, CA
Takeda, Osaka, Japan
Teva, Petah Tikva, Israel
Verge Genomics, CA
Vertex, Boston, MA

Foundations and not-for-profit consortia

Although for understandable reasons the ALS research funding landscape in the past was divided between a number of excellent foundations and federal funding sources, there is an exciting and positive trend toward overall strategic consultation and partnership on specific initiatives. From its launch, Target ALS has sought to collaborate, not to compete. We are delighted to be actively engaged in a mosaic of shared scientific and funding initiatives to get the important work done. Some of our key partners, today and over the past years, have been:

ALS Association
ALSFAC
Muscular Dystrophy Association
National Institute of Neurological Disorders and Stroke
New York Genome Center
Northeast ALS Consortium
Packard Center
Prize4Life
Project A.L.S.